# The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus

> **NCT01342042** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **BIOLOGICAL:** rExenatide-4

## Key facts

- **NCT ID:** NCT01342042
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2011-04-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342042, "The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01342042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*